aggressively with beta-blockers, aspirin, and hypolipidaemic agents (usually a statin). If coronary arterial spasm seems a likely aetiological agent in such a patient, I also prescribe a vasodilator, i.e. a calcium channel blocker, an ACE inhibitor, or an angiotensin receptor blocker. These patients represent a very interesting subset of individuals with myocardial infarction. I am convinced that they will continue to be the subject of clinical investigation in the future in an effort to understand the pathophysiological process that results in their transient episode of coronary arterial obstruction.
Economics of coronary stenting and GPIIb/IIIa blockade

See page 1476 for the article to which this Editorial refers
Multiple studies have shown that the use of GPIIb/ IIIa blockade can reduce cardiovascular events in the setting of percutaneous coronary intervention [1] [2] [3] . The EPISTENT trial was particularly interesting and timely [4] . In EPISTENT, 2399 patients undergoing coronary revascularization were randomized to three arms: stent plus placebo, stent plus abciximab, and PTCA plus abciximab. The primary end-point was the composite at 30 days of death, myocardial infarction, or coronary ischaemia requiring urgent revascularization. At 30 days and 6 months, major adverse cardiac event-free survival was highest in the stent plus abciximab group. Abciximab resulted largely in a decrease in acute myocardial infarction within 1 month while stents decreased additional revascularization at 6 months. In diabetics, abciximab reduced revascularization rates as well.
In the current issue, Zwart-van Rijkom and van Hout extend the results of the EPISTENT trial to include an economic analysis [5] . EPISTENT was conducted in the United States and Canada, but the economic study presented in this issue was based on Dutch unit costs, priced in 1998 Euros. Costs at 6 months were highest in the stent plus abciximab group and lowest in the PTCA plus abciximab group. Cost effectiveness was evaluated as the incremental cost per event averted by adding abciximab to stent plus placebo and as the incremental cost per event averted by adding a stent to PTCA plus abciximab. The cost per event averted of abciximab was Euros 14 198 and of a stent Euros 12 228. In diabetics, the cost per event averted of abciximab was Euros 2167 and of a stent Euros 8040. Due to uncertainty in the cost and efficacy measures, abciximab may be cost saving in diabetics. Studying the subgroup with diabetes shows that the cost-effectiveness of therapy can be much greater in higher risk subgroups and that therapy can then be targeted to such subgroups [6] . The study by Zwart-van Rijkom and van Hout is limited by the design of the EPISTENT study, as the investigators well recognize. The use of clinical data from one geographical area for use in another geographical area for an economic study assumes that the patterns of care are similar. Often in economic studies there are either no local or insufficient local data to conduct the economic study, such that data from other countries are all that is available. Where there is a local data subset, this subset should be compared to the non-local data for the patterns of clinical variables and outcomes. If local data vary significantly from non-local data, then an economic analysis based on non-local data may be seriously limited. In the present study, there was no arm receiving PTCA plus placebo. This would have been a nice addition analytically, but difficult practically and perhaps ethically. If a PTCA plus placebo group were available, then the incremental cost-effectiveness of stent to PTCA in the absence of abciximab and of abciximab to placebo in the absence of stenting would have been available. It is possible that in these situations cost per event averted would have been lower than those observed. The costs per event averted which are presented here would remain relevant as the cost-effectiveness of the second therapy (stent or abciximab) after the first therapy (stent or abciximab) had been given. However, the economics of GPIIb/IIIa blockade to PTCA have been studied in several clinical trials [7] [8] [9] , as have the economics of coronary stenting in the absence of GPIIb/IIIa blockade [10] . The clinical benefits of GPIIb/IIIA blockade and coronary stenting have been achieved, at most, by a modest increase in cost [7] [8] [9] [10] . The biggest limitation of Zwart-van Rijkom and van Hout's paper is that a more formal cost-utility analysis could not be performed. In such an analysis, the cost-effectiveness ratio is expressed as the incremental cost per quality adjusted life years (QALYs) gained [11] . QALYs are calculated as survival multiplied by the utility of that survival, discounted in future years. Utility is a term from economic theory that describes the preference for one health state over another. Utility may be measured by using rating scales such as the EuroQol [12] or more direct measures of patient preference such as the time trade-off [13] or standard gamble [14] . Such measurements were not made in EPISTENT, having just become popular in clinical trials quite recently.
While a cost-utility analysis was not possible, an analysis using cost per life year saved was possible. However, there was little difference in survival, and the ratio would have been unstable. Furthermore, by preventing events patients may feel better, such that an analysis based on cost per life year gained would not include the benefit of stents or abciximab on health-related quality of life. Survival measured at 6 months may also not include the full benefit of abciximab or stenting on survival if the study were carried out longer. In the end, for therapy to be efficacious it must affect survival, utility, or both. Proving efficacy of therapy by effects on survival or utility may be quite challenging, leading to analyses based on more readily available data, such as that presented here.
There are two problems with cost-effectiveness analyses based on cost per event averted. The first is that it is difficult to determine at what threshold of cost per event averted that therapy is warranted. The second problem is more subtle, in that events have costs attached to them, such that costs are reflected in both the numerator and denominator of the cost effectiveness ratio.
As people read economic analyses, the question immediately arises as to how such analyses can help in clinical decision making. Efforts to use costeffectiveness ratios as a primary tool for policymaking purposes have not been particularly successful [15] . Also, cost-effectiveness analyses have varied methodologically, making comparisons difficult. In an effort to standardize cost-effectiveness analyses, the United States Public Health Service has adopted a set of standard recommendations for costutility analyses [16] . While difficult to apply to actual studies, those performed according to these guidelines will allow cost-utility ratios to be compared across multiple studies across multiple disciplines.
In the study by Zwart-van Rijkom and van Hout, we must take a more limited view of the economic analysis. In higher risk groups, such as diabetics, there may be cost savings of adding abciximab to stents, which, combined with the better outcome with stents, is a situation in which abciximab dominates placebo. In this case, the decision to use abciximab is easy. In lower risk groups, the decision making can be difficult and we are left with some degree of uncertainty as to the cost effectiveness of expensive therapy. One thing has become certain, as expensive medical procedures and pharmacological therapy have expanded, society has increasingly come to demand that therapy provide benefit to an extent that it is worth the money spent, and that data are provided showing that this is the case.
